370 related articles for article (PubMed ID: 7524903)
1. Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues.
Sharief FS; Mohler JL; Sharief Y; Li SS
Biochem Mol Biol Int; 1994 Jun; 33(3):567-74. PubMed ID: 7524903
[TBL] [Abstract][Full Text] [Related]
2. Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues.
Li SS
Kaohsiung J Med Sci; 1996 Aug; 12(8):441-7. PubMed ID: 8774111
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of prostatic acid phosphatase and prostate-specific antigen mRNA levels in hyperplastic prostate stimulated with steroid hormones and growth factors.
Dulińska J; Laidler P; Labedź M
Acta Biochim Pol; 2002; 49(2):357-68. PubMed ID: 12362977
[TBL] [Abstract][Full Text] [Related]
4. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
5. Analysis of prostatic fluid in prostatic disease.
Grayhack JT; Wendel EF; Lee C; Oliver L
Cancer Treat Rep; 1977; 61(2):205-10. PubMed ID: 68824
[TBL] [Abstract][Full Text] [Related]
6. Lactate dehydrogenase isoenzymes in benign and malignant prostatic tissues.
Mazzuca A; Lalanne GM
Boll Soc Ital Biol Sper; 1980 Apr; 56(7):690-2. PubMed ID: 6160867
[TBL] [Abstract][Full Text] [Related]
7. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
8. Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array.
Porkka KP; Visakorpi T
J Pathol; 2001 Jan; 193(1):73-9. PubMed ID: 11169518
[TBL] [Abstract][Full Text] [Related]
9. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between prostate-specific acid phosphatase RFLP genotypes and prostatic cancer or benign prostatic hyperplasia.
Leskelä S; Virkkunen P; Lukkarinen O; Winqvist R; Vihko P
Cytogenet Cell Genet; 1991; 57(1):9-10. PubMed ID: 1713142
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum lactate dehydrogenase, phosphohexose isomerase, aldolase and hexokinase in prostatic carcinoma.
Yeshowardhana
Indian J Physiol Pharmacol; 1985; 29(1):33-8. PubMed ID: 2414222
[TBL] [Abstract][Full Text] [Related]
15. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
[TBL] [Abstract][Full Text] [Related]
16. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP
Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
18. [Expression of COX-2 in prostatic cancer and benign prostatic hyperplasia].
Zang T; Sun F; Li Y
Zhonghua Wai Ke Za Zhi; 2001 Sep; 39(9):702-3. PubMed ID: 11769607
[TBL] [Abstract][Full Text] [Related]
19. Prostatic acid phosphatase and prostate-specific antigen in prostate cancer.
Kuriyama M; Loor R; Wang MC; Lee C; Killian CS; Papsidero LD; Inaji H; Nishiura T; Slack NH; Murphy GP; Chu TM
Int Adv Surg Oncol; 1982; 5():29-49. PubMed ID: 6178696
[No Abstract] [Full Text] [Related]
20. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma.
O'Neill AJ; Boran SA; O'Keane C; Coffey RN; Hegarty NJ; Hegarty P; Gaffney EF; Fitzpatrick JM; Watson RW
Prostate; 2001 May; 47(3):183-8. PubMed ID: 11351347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
